Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review.
COVID-19
antibody
cancer
seroconversion
vaccination
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
08
2021
accepted:
18
10
2021
entrez:
22
11
2021
pubmed:
23
11
2021
medline:
23
11
2021
Statut:
epublish
Résumé
After the results of phase III vaccine studies became available, the leading oncology societies recommended two doses of COVID-19 vaccination to all patients with cancer with no specific recommendation for tumor type and active treatments. However, the data on the COVID-19 vaccine efficacy in cancer patients is limited due to exclusion of cancer patients from most vaccine clinical trials. Therefore, we systemically reviewed the available evidence evaluating the antibody responses in cancer patients. We conducted a systematic search from the Pubmed database and calculated risk differences (RD) and 95% confidence intervals (CI) to compare seroconversion rates between cancer patients and controls using the Review Manager software, version 5.3. Our systematic search retrieved a total 27 studies and we included 17 studies with control arms in the analyses. Cancer patients had significantly lower seroconversion rates (37.3%) than controls (74.1%) (RD: -0.44, 95% CI: -0.52, -0.35, p<0.001) with first vaccine dose. After two doses, the seroconversion rates were 99.6% in control arm and 78.3% in cancer patients (RD: -0.19, 95% CI: -0.28, -0.10, p<0.001). The difference in seroconversion rates was more pronounced patients with hematologic malignancies (72.6%) (RD: -0.25, 95% CI: -0.27, -0.22, p<0.001) than patients with solid tumors (91.6%) (RD: -0.09, 95% CI: -0.13, -0.04, p<0.003) and patients in remission (RD: -0.10, 95% CI: -0.14, -0.06, p<0.001). In conclusion, COVID-19 vaccine seroconversion rates were significantly lower in patients with hematological malignancies and patients under active treatment. Further research focusing on the approaches to improve vaccine efficacy and exploration of novel treatment options is urgently needed for these patients.
Identifiants
pubmed: 34804957
doi: 10.3389/fonc.2021.759108
pmc: PMC8599356
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
759108Informations de copyright
Copyright © 2021 Guven, Sahin, Kilickap and Uckun.
Déclaration de conflit d'intérêts
FMU was employed by Ares Pharmaceuticals, LLC and was a consultant for Aptevo Therapeutics and for Reven Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Br J Haematol. 2021 Sep;194(6):999-1006
pubmed: 34085278
Ann Oncol. 2021 May;32(5):579-581
pubmed: 33582237
Cancer Cell. 2021 Aug 9;39(8):1037-1038
pubmed: 34242571
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nat Rev Immunol. 2021 Apr;21(4):195-197
pubmed: 33674759
N Engl J Med. 2021 Sep 23;385(13):1184-1195
pubmed: 34347950
Lancet Haematol. 2021 Jun;8(6):e389-e392
pubmed: 33887255
Front Immunol. 2021 May 03;12:629102
pubmed: 34012431
Med Lett Drugs Ther. 2021 Sep 20;63(1633):145-146
pubmed: 34550960
Ann Oncol. 2021 Oct;32(10):1294-1295
pubmed: 34171494
BMJ Support Palliat Care. 2020 Jul 14;:
pubmed: 32665259
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Eur J Cancer. 2021 Jun;150:1-9
pubmed: 33882374
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2
pubmed: 34214473
Eur J Cancer. 2021 Sep;154:4-6
pubmed: 34217909
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
J Clin Virol. 2021 Jan;134:104690
pubmed: 33253926
JAMA Oncol. 2021 Oct 1;7(10):1507-1513
pubmed: 34236381
Nat Med. 2021 Jul;27(7):1280-1289
pubmed: 34017137
Viruses. 2021 Apr 20;13(4):
pubmed: 33924168
Br J Haematol. 2021 Oct;195(2):186-193
pubmed: 34196388
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Nat Commun. 2022 Feb 14;13(1):864
pubmed: 35165284
Blood. 2020 Sep 3;136(10):1134-1143
pubmed: 32688395
Nat Cancer. 2020 Oct;1(10):946-964
pubmed: 35121872
Ann Oncol. 2020 Aug;31(8):1087-1088
pubmed: 32360743
N Engl J Med. 2021 Aug 12;385(7):661-662
pubmed: 34161700
Cell Mol Immunol. 2021 Aug;18(8):2040-2041
pubmed: 34267334
Science. 2021 Apr 30;:
pubmed: 33931567
N Engl J Med. 2021 Sep 23;385(13):1244-1246
pubmed: 34379917
Blood. 2021 Jul 1;137(26):3674-3676
pubmed: 33861315
Leuk Lymphoma. 2021 Dec;62(13):3308-3310
pubmed: 34308748
JAMA Oncol. 2021 Aug 1;7(8):1133-1140
pubmed: 34047765
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32350047
Open Forum Infect Dis. 2021 Jun 30;8(7):ofab353
pubmed: 34337100
Ann Oncol. 2021 Aug;32(8):1053-1055
pubmed: 33932508
J Hematol Oncol. 2021 May 17;14(1):81
pubmed: 34001183
Med Oncol. 2021 Jul 8;38(8):92
pubmed: 34235592
Leukemia. 2021 Dec;35(12):3573-3577
pubmed: 34023850
Cancers (Basel). 2021 Aug 26;13(17):
pubmed: 34503127
Cancer Discov. 2021 Feb;11(2):233-236
pubmed: 33355178
Ann Oncol. 2018 Jun 1;29(6):1354-1365
pubmed: 29688266
Nat Hum Behav. 2021 Jul;5(7):947-953
pubmed: 33972767
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
Nat Rev Clin Oncol. 2021 May;18(5):313-319
pubmed: 33723371
Br J Haematol. 2021 Sep;194(6):1010-1015
pubmed: 34132395
Clin Infect Dis. 2014 Feb;58(3):e44-100
pubmed: 24311479
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
Diagnostics (Basel). 2021 Apr 09;11(4):
pubmed: 33918840
Br J Cancer. 2011 May 24;104(11):1670-4
pubmed: 21540859
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Leukemia. 2021 Sep;35(9):2703-2705
pubmed: 33986431
Am J Hematol. 2021 Oct 1;96(10):1195-1203
pubmed: 34185336
Ann Oncol. 2021 Aug;32(8):1051-1053
pubmed: 33932501
Lancet Haematol. 2021 Aug;8(8):e542-e544
pubmed: 34224667
Int J Oncol. 2021 Feb;58(2):145-157
pubmed: 33491759
Int J Mol Med. 2021 Jun;47(6):
pubmed: 33846767
Front Cell Dev Biol. 2020 Feb 11;8:17
pubmed: 32117960
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Int J Cancer. 2021 Jan 15;148(2):363-374
pubmed: 32683687
Clin Exp Med. 2022 May;22(2):319-323
pubmed: 34283338
Nat Cancer. 2021 Apr;2(4):392-399
pubmed: 34661163
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
Ann Intern Med. 2021 Sep;174(9):1330-1332
pubmed: 34125572
Ann Oncol. 2021 Jan;32(1):113-119
pubmed: 33098994
J Oncol Pharm Pract. 2020 Jul;26(5):1289-1294
pubmed: 32423324
Cancer Cell. 2021 Aug 9;39(8):1028-1030
pubmed: 34242572
Cancers (Basel). 2020 Aug 10;12(8):
pubmed: 32785162
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Signal Transduct Target Ther. 2021 Feb 2;6(1):48
pubmed: 33531462
J Hematol Oncol. 2021 May 31;14(1):86
pubmed: 34059088
Nature. 2021 Jul;595(7868):572-577
pubmed: 34044428
MMWR Morb Mortal Wkly Rep. 2021 May 21;70(20):753-758
pubmed: 34014909
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2
pubmed: 34133951
Sci Data. 2020 Oct 8;7(1):345
pubmed: 33033256
Blood Cancer J. 2021 Aug 2;11(8):138
pubmed: 34341335